Abbott Laboratories (NYSE:ABT) Shares Acquired Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on February 19th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on January 29th. The trade occurred in the Representative’s “KEAN FAMILY PARTNERSHIP” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.

Abbott Laboratories Trading Up 0.0%

Shares of NYSE ABT traded up $0.02 during trading on Friday, hitting $112.21. 6,989,430 shares of the company traded hands, compared to its average volume of 12,036,590. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $195.11 billion, a P/E ratio of 30.16, a P/E/G ratio of 1.79 and a beta of 0.75. The company has a 50-day moving average price of $118.46 and a 200-day moving average price of $125.84. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the business posted $1.34 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds have recently added to or reduced their stakes in the business. Carr Financial Group Corp boosted its stake in Abbott Laboratories by 2.0% in the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after acquiring an additional 76 shares during the period. Tortoise Investment Management LLC boosted its position in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after purchasing an additional 77 shares during the period. Gemmer Asset Management LLC increased its position in Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after buying an additional 78 shares during the period. Bridgewater Advisors Inc. lifted its stake in Abbott Laboratories by 0.6% in the second quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after buying an additional 79 shares during the last quarter. Finally, Global Financial Private Client LLC grew its position in shares of Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after acquiring an additional 79 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.46% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein cut their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. BTIG Research reduced their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Daiwa Securities Group reduced their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Exact Sciences stockholders approved Abbott’s acquisition proposal (preliminary results showed >99% of votes cast and ~67% of outstanding shares represented), clearing a key shareholder hurdle and advancing Abbott’s expansion into cancer screening/diagnostics — a strategic deal that should broaden revenue mix and long-term growth prospects. Exact Sciences Stockholders Approve Acquisition by Abbott
• Positive Sentiment: Abbott’s board declared its 409th consecutive quarterly dividend at $0.63/share, reinforcing a reliable income profile that supports shareholder confidence and may attract income-oriented investors. Abbott declares 409th consecutive quarterly dividend
• Positive Sentiment: Abbott reported positive clinical results for its Amulet 360 Left Atrial Appendage (LAA) occluder presented at the AF Symposium — a favorable outcome for the company’s structural-heart/device pipeline that could support future market adoption and revenue growth in electrophysiology/cardiology. Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
• Neutral Sentiment: Abbott’s board approved governance changes to streamline the board (smaller board size). This is a modest corporate-governance move that could slightly improve oversight/efficiency but is unlikely to drive material near-term earnings changes. Abbott Laboratories Streamlines Governance With Smaller Board
• Neutral Sentiment: Media comparisons (BSX vs ABT) highlight Abbott’s valuation appeal, CGM momentum and strategic deals as advantages vs. Boston Scientific — useful context for investors but not a direct corporate action. BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
• Negative Sentiment: BTIG cut its price target for ABT to $140, which may temper near-term analyst-driven upside and investor enthusiasm despite the company’s strategic wins; analyst revisions can influence sentiment and trading volume. BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.